검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | dendritic cell vaccine therapy (dendritic cell vaccine therapy) Life Research Technologies GmbH·Unspecified Adult Solid Tumor, Pro… ORR 0.15% |
|---|---|
Overview Program | dendritic cell vaccine therapy |
Overview Company | Life Research Technologies GmbH |
Overview Modality | ANTIBODY |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | checkpoint-mediated protection, and lesion-supportive inflammatory remodeling |
MoA Biomarker | biomarker for stratifying breast cancer patients according to prognosis and likely treatment benefit |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 0.15% |
Clinical ORR | 0.15% |
Clinical PFS | 9.5 |
Clinical OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00323115 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | dendritic cell vaccine therapy (dendritic cell vaccine therapy) Life Research Technologies GmbH·Unspecified Adult Solid Tumor, Pro… ORR 0.15% |
|---|---|
Overview Program | dendritic cell vaccine therapy |
Overview Company | Life Research Technologies GmbH |
Overview Modality | ANTIBODY |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | checkpoint-mediated protection, and lesion-supportive inflammatory remodeling |
MoA Biomarker | biomarker for stratifying breast cancer patients according to prognosis and likely treatment benefit |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.. Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable. We retrospectively evaluated the safety and efficacy of neoantigen peptid… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 0.15% |
Clinical ORR | 0.15% |
Clinical PFS | 9.5 |
Clinical OS | 28 |
Clinical Result source | ClinicalTrials.gov NCT00323115 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교